Nom du produit:1-(5-Bromo-1H-indazol-3-yl)ethanone
IUPAC Name:1-(5-bromo-1H-indazol-3-yl)ethan-1-one
- CAS：886363-74-2
- Formule moléculaire：C9H7BrN2O
- Pureté：95%
- Numéro de catalogue：CM231240
- Poids moléculaire：239.07
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:886363-74-2
- Formule moléculaire:C9H7BrN2O
- Point de fusion:-
- Code SMILES:CC(C1=NNC2=C1C=C(Br)C=C2)=O
- Densité:
- Numéro de catalogue:CM231240
- Poids moléculaire:239.07
- Point d'ébullition:403.8±25.0°C at 760 mmHg
- N° Mdl:MFCD07374362
- Stockage:Keep in a tight container and store at 2°C~8°C，protect from light
Category Infos
- Indazoles
- Indazoles are a class of organic heterocyclic compounds, also known as 1,2-diazaindene and benzopyrazole. Indazole is a good bioisomer of phenol, which is more lipophilic than phenol and less prone to phase I and II metabolism. Indazole derivatives have a wide range of biological activities, and it has been confirmed that indazole compounds have anti-tumor, analgesic, anti-inflammatory and other drug activities. Anticancer is the most important application field of indazole drugs. Renal cell carcinoma, solid tumor, nausea and vomiting caused by chemotherapy and leukemia are the main indications of this structural backbone drug.
Column Infos
- Voydeya
- Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Voydeya is the first drug in the class to be cleared for marketing anywhere in the world and has been licensed for use as an add-on therapy to C5 inhibitors, like its own Soliris (eculizumab) and Ultomiris (ravulizumab) products, in patients who don’t get a satisfactory response from C5 drugs alone. Voydeya (danicopan) is a first-in-class oral Factor D inhibitor. Voydeya has been granted Breakthrough Therapy designation by the US Food and Drug Administration and PRIority MEdicines (PRIME) status by the European Medicines Agency. Voydeya has also been granted Orphan Drug Designation in the US, EU and Japan for the treatment of PNH.
Recherche 
+86 21 5895 0110 
